Efficacy of Telitacicept in treating IgA vasculitis nephritis: a two-case report
Telitacicept, a B lymphocyte stimulator/A proliferation-inducing ligand dual-target fusion protein, mainly used for IgA nephropathy and systemic lupus erythematosus. We present two cases where adult patients with IgA vasculitis (IgAV) nephritis were successfully treated with Telitacicept, experienced no adverse reactions during the follow-up. Therefore, Telitacicept represents a promising additional treatment option for patients suffering from IgA vasculitis (IgAV).
Authors
- Dexia Kong (ORCID: https://orcid.org/0000-0002-5311-1906)
- Rongrong Hu (ORCID: https://orcid.org/0000-0002-2238-3431)
- Zhiyong Guo (ORCID: https://orcid.org/0000-0002-5458-6268)
- Jing Xu (ORCID: https://orcid.org/0000-0002-9276-5128)
- Shuangxi Li (ORCID: https://orcid.org/0000-0002-0566-7651)
- Xiaodong Mei (ORCID: https://orcid.org/0000-0002-7629-9200)
- Qi Bian (ORCID: https://orcid.org/0000-0002-5440-9333)
Institutions
- Second Military Medical University (CN)
- Changhai Hospital (CN)
- Chinese People's Liberation Army (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-05-01
- DOI
- https://doi.org/10.3389/fimmu.2025.1564242
- Citations
- 3
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 4.29
Funders
- National Natural Science Foundation of China